# Critical evaluation — v0.7.1

## Overall portfolio assessment: 8.2/10

Version 0.7.1 closes two concrete gaps in v0.7.0. The locked perfusion-proxy workflow now covers all
four available S-BIAD3159 fields, and the independent breast cohort advances from a label-only audit to
real ERBB2 extraction from two native provider Zarr matrices. The scientific advance is meaningful but
component-level: the external tissues and assays are still not co-registered with the RCC section.

| Perspective | Score | Remaining objection |
|---|---:|---|
| Biologics discovery hiring manager | 8.2/10 | The evidence chain is broad but cannot support a dose, target or antibody-format decision. |
| Methods reviewer | 8.0/10 | Perfusion and expression are independent external sections, not a matched mechanistic validation. |
| Skeptical statistician | 8.0/10 | Four image fields and two breast sections are descriptive; independent animal or donor replication is unavailable. |
| Software engineer | 9.2/10 | The provider-schema reader is isolated, typed, regression-tested and integrated into the full package and CLI. |
| Reproducibility auditor | 9.0/10 | Compact outputs reproduce the Colab hash chain and the source, wheel and sdist are rebuilt from the merged tree. |

## What still prevents a 9/10 scientific release

A matched dataset must contain administered antibody, functional vasculature, calibrated surface target,
tissue geometry and sample-level raw endpoints. The current release correctly abstains instead of
combining independent proxies into an absolute reachability number.
